Schmidt Amy E, Bajaj S Paul
Departments of Pharmacological & Physiological Sciences and Internal Medicine, Saint Louis University Health Sciences Center, MO 63110, USA.
Trends Cardiovasc Med. 2003 Jan;13(1):39-45. doi: 10.1016/s1050-1738(02)00210-4.
Factor IX (FIX) consists of an N-terminal gamma-carboxyglutamic acid (Gla) domain followed by two epidermal growth factor (EGF)-like domains, and the C-terminal serine protease domain. During physiologic coagulation, one of the activators of FIX is the FVIIa/tissue factor (TF) complex. In this reaction, the Gla and EGF1 domains of FIX are thought to interact with TF. The FIXa that is generated then combines with FVIIIa on the platelet surface to activate FX in the coagulation cascade. In this assembly, the protease domain and possibly the EGF2 domain of FIXa are thought to provide the primary specificity in binding to FVIIIa. Disruption of the interaction of FIX/FX with TF and of the FIXa:FVIIIa interface may provide a pharmacologic target as an alternative strategy for the development of antithrombotic agents.
凝血因子IX(FIX)由一个N端γ-羧基谷氨酸(Gla)结构域、两个表皮生长因子(EGF)样结构域以及C端丝氨酸蛋白酶结构域组成。在生理性凝血过程中,FIX的激活剂之一是FVIIa/组织因子(TF)复合物。在该反应中,FIX的Gla和EGF1结构域被认为与TF相互作用。随后生成的FIXa与血小板表面的FVIIIa结合,在凝血级联反应中激活FX。在这个组装过程中,FIXa的蛋白酶结构域以及可能的EGF2结构域被认为在与FVIIIa结合时提供主要特异性。FIX/FX与TF之间相互作用以及FIXa:FVIIIa界面的破坏可能为抗血栓药物开发提供一种替代策略的药理学靶点